
France · Medical devices startup
Japet Medical is a French MedTech startup founded in 2016, located in Loos, Hauts-de-France.
Funding reportedLast round: Convertible note
Follow Japet Medical and see its new rounds in your feed.Start following
Japet Medical is a French MedTech startup founded in 2016, located in Loos, Hauts-de-France.
The company specializes in designing and manufacturing motorized medical exoskeletons aimed at preventing back pain and musculoskeletal disorders in the workplace. Their flagship product, the Japet.W+, is a powered lower-back exoskeleton that adjusts in real-time to user movements, providing support and relieving lumbar pain. It is certified as a Class IIa medical device and is effective for individuals suffering from both chronic and acute lower back pain. Japet Medical focuses on integrating exoskeletons into various industries, including aeronautics, logistics, and healthcare, to enhance worker safety and health. The company also offers consulting services to assist businesses in deploying these devices effectively. Additionally, they support the employment of workers with disabilities by providing exoskeletons that help maintain their ability to work. With a mission to preserve human capital, Japet Medical combines medical science, textile expertise, and robotics to improve workplace health and productivity.
Funding, as reported
What they build
Known for
support ergonomique robotiséhealth careexosquelette francesupport de la tête en mouvement robotiséwearable medicineprévention tmsexosquelette ergonomiqueergonomiesstsupport têtesupport de la prévention des tmsfabrication françaisetransportation_logisticsdistributionmanufacturingsupport musculaire robotisé
Built with from their website
Google Tag ManagerAmazon CloudFrontWordPress.orgHREF LangOVHcloudFont AwesomeYouTubeGoogle WorkspaceCloudFlareViewport Meta
CookieYesHubspotCloudflare WAFWebflow HostingGoogle MeetCloudFlare CDNPriority HintsGoogle Font API
Add your raise, your deck and your story, and put Japet Medical in front of investors. Or tell us what we have wrong.